NLS Pharmaceutics (NLSP) has released an update.
NLS Pharmaceutics is undertaking a significant restructuring effort by proposing an ordinary capital increase of CHF 29,887.20 and converting a portion of its common shares into preferred shares and participation certificates. This move aims to ensure the company’s survival and make it suitable for future strategic transactions. Investors and shareholders will find this capital restructuring crucial as it could impact the company’s financial health and stock performance.
For further insights into NLSP stock, check out TipRanks’ Stock Analysis page.
